For instance, mutations in isocitrate dehydrogenase (IDH) and the methylation status of O6-methylguanine-DNA methyltransferase (MGMT) have emerged as crucial indicators of GBM prognosis. This evidence concerns the gene IDH1 and glioblastoma.